43
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Global resource shortages during COVID-19: Bad news for low-income countries

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The world’s wealthiest countries have been gripped by resource shortages, including shortages of personal protective equipment (PPE) and ventilators, during the coronavirus disease 2019 (COVID-19) pandemic [1, 2]. In order to guarantee these resources for their own nation’s health workers, governments around the world are bargaining for their share in a strangled global supply chain. For example, countries such as Taiwan, Thailand, Russia, Germany, the Czech Republic, and Kenya have blocked the export of all face masks [3]. There have additionally been reports of PPE and ventilator exports being intercepted and delivered to the country with the highest bid, aptly referred to as acts of “modern piracy” [3]. Undeniably, securing PPE for health workers and respiratory devices for patients is a critical part of overcoming the COVID-19 pandemic. However, we must not forget that for many hospitals, these resources have never been in abundant supply. Instead, PPE and respiratory devices are scarce commodities for many hospitals in low-income countries (gross national income per capita ≤US$1,025) under the best of circumstances, with health crises such as the 2014–2016 West African Ebola epidemic highlighting gaps in the global PPE supply [4]. Indeed, deaths from Ebola were concentrated among healthcare providers, with 8.1% of the total health workforce in Liberia and 6.9% in Sierra Leone dying from Ebola [5]. Hospitals in low-income countries rely on the same supply chains as hospitals in wealthy countries to import medical supplies but have significantly less bargaining power to secure resources [6]. Therefore, resource grabs by high-income countries will likely have devastating effects on low-income countries as COVID-19 continues to spread globally [6, 7]. Already, UNICEF reports that the organization has only been able to acquire one-tenth of the 240 million masks requested by low-income countries [6]. To better elucidate COVID preparedness in low-income countries, we combined data from all service provision assessments (SPAs) conducted in nationally representative surveys of hospitals within the past 5 years in low-income countries, which included Afghanistan, Democratic Republic of the Congo (DRC), Haiti, Nepal, and Tanzania [8]. Our analysis of hospital general clinics confirms limited quantities of PPE, with only 24% to 51% of hospitals reporting any type of face mask, 22% to 92% medical gowns, and 3% to 22% eye protection (Fig 1). Sanitation supplies were also scarce, with 52% to 87% of hospitals recording soap plus running water and 38% to 56% alcohol-based hand sanitizer. We found further gaps in ability to provide care for respiratory conditions, again demonstrating under-investment in hospital-based services [9]. The hospitals analyzed lacked pulse oximeters (12%–48% available), oxygen tanks (10%–82%), and bag-masks necessary for basic resuscitation (28%–45%). As has been noted by prior studies, more advanced respiratory support such as intensive care unit (ICU) care and ventilators are even scarcer [10]. 10.1371/journal.pntd.0008412.g001 Fig 1 Availability of hospital clinic PPE, sanitation, and functional diagnostics and therapeutics across nationally representative samples of hospitals in 5 low-income countries. PPE, personal protective equipment. An important part of addressing the COVID-19 pandemic is adequate testing at the community level. In addition to current shortages of COVID-19 testing globally [2, 11], the ability to offer COVID-19 testing will likely be further constrained in low-income countries due to already limited diagnostic capacity. For example, SPA data show that fewer than 20% of hospitals, besides those in Tanzania, were able to measure CD4 count for HIV monitoring. Additionally, there is limited ability to provide routine childhood vaccination in hospitals in Afghanistan (35%), DRC (14%), Haiti (57%), and Nepal (60%), underscoring the potential for gaps in the ability to transport, store, and deliver vaccines if eventually available for COVID-19. With COVID-19 causing unprecedented resource shortages in the world’s wealthiest countries, already limited healthcare commodities will likely become even scarcer in low-income countries. There have been some rapid adjustments in the global supply chain, with China increasing its output of medical masks to 12 times previous levels [3]. But with prices for PPE and respiratory devices soaring, which hospitals will be able to afford them? In the West African Ebola epidemic, investment in high-quality PPE and infection control training were important components of halting the spread of disease [12], and where this was lacking, nosocomial spread was clearly worse [13]. In response to the current COVID-19 challenge, countries such as Afghanistan and Nepal have started manufacturing their own supplies of PPE and basic life support equipment, but this is not likely to be a feasible approach for all countries [14, 15]. Continued local as well as international action is needed to ensure access to PPE for all health workers and respiratory support for all patients, not just for those living in resource-abundant countries. As COVID-19 therapeutics and vaccines emerge, additional international commitment will be necessary to ensure global access. Equity requires no less.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Critical Supply Shortages — The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic

          New England Journal of Medicine
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Sourcing Personal Protective Equipment During the COVID-19 Pandemic

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19 and risks to the supply and quality of tests, drugs, and vaccines

              Emergency efforts are underway to find optimum medical products to prevent infection and diagnose and treat patients during the coronavirus disease 2019 (COVID-19) pandemic. Production and supply chains for COVID-19 candidate drugs (such as chloroquine and hydroxychloroquine), and for many other essential medical products, are being impaired by this crisis. 1 Supply chains for vital drugs for other diseases (such as systemic lupus erythematosus) are being disrupted because they are being repurposed to use against COVID-19, without adequate supporting evidence. Without preparation for the quality assurance of diagnostic tests, drugs, and vaccines, the world risks a parallel pandemic of substandard and falsified products. Interventions are needed globally to ensure access to safe, quality assured, and effective medical products on which the world's population will depend. History provides us with warnings. Quackery was rampant during the Great Plague of the 17th century. When cinchona bark became the treatment for malaria in the 17th century, it was adulterated on a vast scale. After World War 2, penicillin shortages led to widespread falsification. 2 Substandard drugs (because of production or supply chain errors) are driven by cost reduction, whereas falsified agents (because of fraud) thrive on shortages, particularly when buyers depart from regulated supply chains. 3 The COVID-19 pandemic threatens a global surge in substandard and falsified medical products, not just for those directly related to COVID-19. Many products essential for COVID-19 treatment and prevention are at risk, including face masks, hand sanitiser, and diagnostic tests, and false claims have been made for prevention and treatment. 4 Many falsehoods proliferate through illegal websites and social media, 5 and these occurrences will mushroom. Poorly substantiated claims about effectiveness of drugs for treating COVID-19 have led to widespread shortages of chloroquine and hydroxychloroquine and to fatal overdoses. 6 Panicked global populations are desperate to procure products that might prevent and treat COVID-19. When chloroquine was used for malaria treatment, falsified versions were common. 7 Paracetamol is at risk; in the past, nephrotoxic substandard and falsified paracetamol syrup caused hundreds of deaths. 8 The Medicine Quality Monitoring Globe scours the internet for reports of substandard and falsified medical products in many languages, giving the general public early warnings of drug quality problems. Multiple diagnostic, therapeutic, and preventive interventions for COVID-19 are being trialed. 9 If products prove to be efficacious against COVID-19, achieving global benefit will require prompt access for all people in need. Drugs must be affordable, quality assured, and not hoarded or diverted from treatment of malaria, autoimmune diseases, or HIV/AIDS. Ineffective interventions, wasting resources, and causing harm should be opposed by robust policies and community-specific public engagement. We need to plan strategically to ensure global manufacture, access, protection, and monitoring of supply chains in the face of unescapable shortages, cost increases, and national hoarding. All our fates are bound together, and any helpful products must be recognised as global assets. The effect on access to other products (eg, HIV diagnostics) must be minimised. Coordinated information-sharing among global medicines regulators on authorisations for clinical trials, Monitored Emergency Use of Unregistered and Investigational Interventions, and off-label use, as well as comprehensive and rapid reporting of shortages of active ingredients and finished products by industry and regulators, are essential to optimise global demand and supply. With in-person inspections suspended by many regulators, greater use of reliance mechanisms and full information-sharing among regulators is vital. 10 Effective regulatory supervision, emergency prequalification, robust authentication measures, and procurement policies supporting quality, with abjuring of national export restriction policies, the informal market, and illegal online websites, combined with trusted public engagement campaigns, will be needed to reduce substandard and falsified medical products. Few nations have medicine regulatory authorities classed by WHO as well functioning and integrated regulatory systems, rendering most populations especially vulnerable to substandard and falsified medical products. Innovative regional mechanisms (eg, the African Vaccine Regulatory Forum) might be part of the solution in this urgency. As efficacious COVID-19 treatments and vaccines are approved, intense global coordinated production, distribution chains, and postmarket surveillance will be needed to protect the general public from manufacturing and supply chain failures, inadequate manufacturing protocols, and criminals selling falsified products. 11 Robust evaluation of diagnostics tests (premarket and postmarket) to ensure accuracy will be vital; bad tests will be worse than no tests. If a drug is shown to be efficacious, devices able to detect whether the product contains the stated amount of active ingredient with appropriate dissolution will be important in supporting postmarket surveillance. Many portable screening devices are available but with scant evidence for their effectiveness. Few data exist to show which agents these devices can detect; none has yet been shown to accurately quantify diverse active ingredients. 12 These devices will need to be integrated into national regulatory standards and WHO's Prevent, Detect and Respond frameworks, using public pharmacopeial standards. 9 Drug quality is vulnerable to fear, desperation, and disinformation. While hoping that the efforts of WHO and global coalitions to accelerate COVID-19 research will provide the means to fight this pandemic, we must ensure that access to affordable quality medical products, particularly in low-resource settings, does not become another casualty.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Negl Trop Dis
                PLoS Negl Trop Dis
                plos
                plosntds
                PLoS Neglected Tropical Diseases
                Public Library of Science (San Francisco, CA USA )
                1935-2727
                1935-2735
                6 July 2020
                July 2020
                : 14
                : 7
                : e0008412
                Affiliations
                [1 ] Harvard Medical School, Boston, Massachusetts, United States of America
                [2 ] Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
                [3 ] Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts, United States of America
                [4 ] Medical Practice and Evaluation Center, Massachusetts General Hospital, Boston Massachusetts, United States of America
                Faculty of Science, Ain Shams University (ASU), EGYPT
                Author notes

                The authors have declared that no competing interests exist.

                Author information
                http://orcid.org/0000-0002-3649-9208
                http://orcid.org/0000-0003-0026-9985
                http://orcid.org/0000-0003-2314-9230
                http://orcid.org/0000-0001-7751-9466
                Article
                PNTD-D-20-00615
                10.1371/journal.pntd.0008412
                7337278
                32628664
                47f8817f-a979-4a0a-8214-321fa0264552
                © 2020 McMahon et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                Page count
                Figures: 1, Tables: 0, Pages: 3
                Funding
                The authors received no specific funding for this work.
                Categories
                Viewpoints
                Medicine and Health Sciences
                Infectious Diseases
                Nosocomial Infections
                Social Sciences
                Economics
                Resource Management
                Shortages
                Engineering and Technology
                Equipment
                Laboratory Equipment
                Ventilators
                Medicine and Health Sciences
                Public and Occupational Health
                Global Health
                Medicine and Health Sciences
                Health Care
                Socioeconomic Aspects of Health
                Medicine and Health Sciences
                Public and Occupational Health
                Socioeconomic Aspects of Health
                People and Places
                Geographical Locations
                Asia
                Afghanistan
                People and Places
                Geographical Locations
                Asia
                Nepal
                Engineering and Technology
                Equipment
                Safety Equipment
                Medicine and Health Sciences
                Public and Occupational Health
                Safety
                Safety Equipment
                Custom metadata
                COVID-19

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article